Pregnancy & MTCT
Pregnancy & HIV MTCT
CROI 2014: Lopinavir or Lamivudine Equally Protective Against HIV During Breast-feeding
- Details
- Category: Pregnancy & HIV MTCT
- Published on Tuesday, 18 March 2014 00:00
- Written by Carole Leach-Lemens
Peri-exposure prophylaxis using either lopinavir/ritonavir (Kaletra) or lamivudine (3TC, Epivir) proved equally protective as infant prophylaxis against HIV infection during 12 months of breast-feeding, according to a report at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this month in Boston.
Protein in Breast Milk May Help Prevent Mother-to-Child HIV Transmission
- Details
- Category: Pregnancy & HIV MTCT
- Published on Wednesday, 30 October 2013 00:00
- Written by Duke University
A natural protein in human breast milk, known as tenascin-C, blocks HIV entry by binding to the viral envelope and preventing it from attaching to host cell co-receptors, possibly helping explain the low rate of mother-to-child HIV infection via breast-feeding, according to research published in the October 21, 2013, advance edition of Proceedings of the National Academy of Sciences.
ICAAC 2013: Raltegravir Appears Safe for Mothers and Babies During Pregnancy
- Details
- Category: Pregnancy & HIV MTCT
- Published on Sunday, 22 September 2013 00:00
- Written by Liz Highleyman
Antiretroviral regimens containing the HIV integrase inhibitor raltegravir (Isentress) were shown to be safe and effective for HIV positive pregnant women and did not cause birth defects in their infants, researchers reported at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this month in Denver.
Do HIV+ Pregnant Women on ART Need Intravenous Zidovudine During Delivery?
- Details
- Category: Pregnancy & HIV MTCT
- Published on Sunday, 22 September 2013 00:00
- Written by Carole Leach-Lemens
Intravenous infusion of zidovudine (AZT; Retrovir) during delivery has been a key component in efforts to prevent mother-to-child HIV transmission, but it may not offer significantly additional protection for women with undetectable viral load, researchers reported in the September 15, 2013, edition of Clinical Infectious Diseases.
IAS 2013: Women Who Start Option B+ ART During Pregnancy Often Lost to Follow-up
- Details
- Category: Pregnancy & HIV MTCT
- Published on Wednesday, 07 August 2013 00:00
- Written by Leslie Odendal
Women who begin HIV treatment during pregnancy or while breastfeeding, prior to the CD4 cell threshold previously recommended for starting treatment (350 cells/mm3), were significantly more likely to be lost to follow-up than women who started treatment at the general treatment threshold, Malawian researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur.
More Articles...
- UNAIDS: HIV Infections among Children Drop by Half in African Countries
- CROI 2013: Small Risk of Birth Defects Due to Efavirenz Confirmed in French Cohort
- Pediatrics Association Recommends Bottle Feeding for Babies of HIV+ Mothers
- HIV11: UK Study Finds HIV+ Women on Antiretroviral Therapy Have Higher Premature Birth Rate
Web Design and Development by